Format

Send to

Choose Destination
Future Oncol. 2019 Jul;15(19):2199-2202. doi: 10.2217/fon-2019-0217. Epub 2019 Jun 19.

Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go.

Author information

1
Department of Urology, UZ Leuven, Leuven, Belgium.
2
Organ Systems, Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
3
Department of Pathology, AZ Klina, Brasschaat, Belgium.
4
Section of Pathological Anatomy, Marche Polytechnic University, School of Medicine, United Hospitals, Ancona, Italy.
5
Department of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
6
Department of Surgery, Cordoba University Medical School, Cordoba, Spain.
7
Department of Pathology & Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.

KEYWORDS:

PD-L1; atezolizumab; basal-type; genitourinary tumors; immunotherapy; luminal-type; lymphocytes; microbiome; urothelial carcinoma

PMID:
31213082
DOI:
10.2217/fon-2019-0217

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center